Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Avalon BioVentures is a San Diego-based venture capital firm founded over 40 years ago, focusing on early-stage biotech and healthcare companies. The firm has a long-standing presence in the biotech sector and emphasizes a hands-on approach, working closely with entrepreneurs to provide capital and operational support. Their notable exit includes the $2.5 billion sale of Synthorx, Inc. to Sanofi.
Avalon BioVentures invests in early-stage life sciences innovations, particularly first-in-class solutions addressing significant medical needs. They target pre-seed, seed, and Series A stages, often engaging with companies that are too early for other investors. Their ABV Accelerator offers integrated operational support, expediting development timelines and optimizing capital efficiency.
Notable companies associated with Avalon BioVentures include Janux Therapeutics, Synthorx, Inc. (sold to Sanofi for $2.5 billion), Sitari, Inc., Fortis Therapeutics, Inc., and Valora.
Avalon BioVentures runs the ABV Accelerator, which provides portfolio companies with essential scientific, operational, and financial resources to expedite their development timelines.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.